Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACEPHEN vs CUPRIMINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.
Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.
Mild to moderate pain,Fever
Wilson disease,Cystinuria,Rheumatoid arthritis (off-label)
325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.
250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.
Terminal elimination half-life: 1.0-1.5 hours in adults with normal renal function. Prolonged to 2-5 hours in hepatic impairment or elderly; requires dose adjustment in severe hepatic disease.
Terminal half-life: 4–6 hours. Clinical context: After discontinuation, urinary copper excretion declines within 2–3 hours but may persist for several days due to tissue redistribution.
Acetaminophen is primarily metabolized in the liver via glucuronidation (UGT1A1, UGT1A6, UGT1A9) and sulfation (SULT1A1, SULT1A3). A minor fraction is oxidized by cytochrome P450 enzymes (CYP2E1, CYP1A2, CYP3A4) to a reactive toxic metabolite (NAPQI), which is normally detoxified by conjugation with glutathione.
Metabolized by oxidation and reduction; primarily renal elimination.
Renal: 90-95% as unchanged drug; tubular secretion and glomerular filtration. Biliary/fecal: <5%.
Renal: ~80% as unchanged drug, biliary/fecal: <5%
Approximately 10-20% bound to serum albumin; extensive tissue binding.
~70% bound, primarily to serum albumin.
Apparent Vd: 0.5-0.7 L/kg (30-40 L in a 70 kg adult). Distributions into CSF and breast milk.
Vd: 0.5–1.0 L/kg (approximately 70 L in adults). Indicates distribution into total body water with moderate tissue binding.
Oral: 85-90% (first-pass metabolism minimal). Rectal: approximately 70-80% of oral bioavailability.
Oral: Approximately 40–70% (variable, reduced by food, especially high-protein meals; administration on empty stomach recommended).
GFR 10-50 m L/min: 650 mg every 6 hours; GFR <10 m L/min: 650 mg every 8 hours.
Contraindicated in severe renal impairment (GFR <30 m L/min). For GFR 30-60 m L/min: reduce dose by 25-50%. Monitor urinary copper and adjust accordingly.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: maximum 2 g/day; Child-Pugh Class C: maximum 1 g/day.
No specific adjustment for Child-Pugh class A or B; use with caution in severe hepatic impairment (Child-Pugh C) due to hepatotoxicity risk. Monitor liver function.
10-15 mg/kg/dose orally every 4-6 hours; maximum 75 mg/kg/day or 4 g/day, whichever is less.
10-20 mg/kg/day orally divided into 2-4 doses; typical starting dose 15 mg/kg/day for Wilson disease (max 1 g/day). Titrate based on urinary copper.
Start at lowest effective dose (325 mg every 6 hours); avoid exceeding 3 g/day unless closely monitored.
Start at lower end of dosing range (250 mg twice daily) due to age-related renal decline; monitor renal function and copper levels.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4,000 milligrams per day, and often involve more than one acetaminophen-containing product.
WARNING: CUPRIMINE can cause severe bone marrow depression leading to aplastic anemia, leukopenia, thrombocytopenia, and agranulocytosis. Deaths have occurred. Monitor blood counts closely.
Risk of severe liver injury with doses >4000 mg/day; use caution with hepatic impairment, chronic alcoholism, malnutrition, or concomitant hepatotoxic drugs; avoid exceeding recommended dose; limit use to 10 days for pain or 3 days for fever unless directed by physician; serious skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) have occurred.
Bone marrow suppression, renal toxicity (proteinuria, hematuria), lupus-like syndrome, myasthenia gravis-like syndrome, rash, and hypersensitivity reactions. Monitor renal function, blood counts, and urinalysis regularly.
Hypersensitivity to acetaminophen or any component of the formulation; severe hepatic impairment or active liver disease.
History of penicillamine-related aplastic anemia or agranulocytosis; concurrent gold therapy, antimalarial drugs, or immunosuppressants; rheumatoid arthritis patients with renal insufficiency.
Alcohol: increased risk of hepatotoxicity. Avoid concurrent use. Food: no significant interaction, but taking with food may reduce minor gastrointestinal irritation.
Take on an empty stomach. Avoid food, especially milk, and any mineral supplements (iron, zinc, calcium) for at least 1 hour before and 2 hours after dosing, as they reduce absorption. Alcohol should be avoided due to potential hepatotoxicity.
Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimesters: NSAID exposure associated with oligohydramnios, premature ductus arteriosus constriction, and fetal renal impairment. Avoid in third trimester.
First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential for growth restriction. Third trimester: Risk of fetal copper deficiency and associated neurological impairment. Pregnancy category D.
Excreted into breast milk in low concentrations (M/P ratio approximately 0.10). Considered compatible with breastfeeding; however, use lowest effective dose for shortest duration given potential for neonatal adverse effects (e.g., thrombocytopenia, renal dysfunction).
Excreted in breast milk. M/P ratio not established. Contraindicated in breastfeeding due to potential for severe adverse effects (hypersensitivity, bone marrow suppression) in the infant.
No standard dose adjustments recommended; however, due to increased plasma volume and metabolism in pregnancy, higher doses may be required to achieve therapeutic effect. Avoid near term.
No standard dose adjustment recommended; use lowest effective dose. Monitor serum copper to maintain therapeutic levels due to altered pharmacokinetics in pregnancy (increased volume of distribution, renal clearance).
ACEPHEN (acetaminophen) is commonly used for mild to moderate pain and fever. Avoid exceeding 4 g/day in adults to prevent hepatotoxicity. In patients with hepatic impairment, reduce maximum daily dose to 2 g. Consider acetylcysteine for overdose. Onset of action is 15-30 minutes orally.
Monitor for proteinuria and hematuria; perform urinalysis weekly initially, then monthly. Penicillamine can cause bone marrow suppression; obtain baseline CBC and differential, then monitor every 2 weeks for first 6 months, then monthly. Drug-induced lupus and myasthenia gravis are rare but serious autoimmune adverse effects. Avoid in patients with a history of penicillin allergy due to potential cross-sensitivity. Administer on an empty stomach at least 1 hour before or 2 hours after meals to enhance absorption. Dose adjustments needed in renal impairment. Pyridoxine (vitamin B6) supplementation (25-50 mg/day) is recommended to prevent deficiency caused by penicillamine. For Wilson disease, monitor 24-hour urinary copper excretion to guide therapy.
Do not exceed 4000 mg (4 grams) in 24 hours.,Avoid drinking alcohol while taking this medication.,Do not combine with other products containing acetaminophen.,Take with food if stomach upset occurs.,Seek immediate medical help if you experience symptoms of liver damage: yellowing of skin/eyes, dark urine, severe abdominal pain.
Take this medication on an empty stomach, at least 1 hour before or 2 hours after meals.,Do not skip doses; take exactly as prescribed and do not double up if a dose is missed.,Report any signs of allergy promptly: rash, itching, fever, joint pain, or swollen lymph nodes.,Contact your doctor immediately if you experience easy bruising, bleeding, or signs of infection such as fever or sore throat.,Inform your doctor about any planned vaccinations; avoid live vaccines while on this medication.,You may need regular blood and urine tests to monitor for side effects.,If you are taking iron supplements or other mineral supplements, take them at least 2 hours apart from this medication to prevent reduced absorption.,Use effective contraception if you are of childbearing age; this drug can harm an unborn baby.,Avoid alcohol as it may increase the risk of liver toxicity.,Notify your dentist about your medication history before any dental procedures.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACEPHEN vs CUPRIMINE, answered by our medical review team.
ACEPHEN is a Non-Opioid Analgesic that works by ACEPHEN (acetaminophen) is a para-aminophenol derivative with analgesic and antipyretic activity. Its mechanism involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, particularly COX-2, reducing prostaglandin synthesis. It has weak peripheral COX inhibition and minimal anti-inflammatory effect.. CUPRIMINE is a Chelating Agent that works by Chelates copper, forming a stable complex that is excreted renally, reducing systemic copper accumulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACEPHEN and CUPRIMINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACEPHEN is: 325-650 mg orally every 4-6 hours as needed; maximum 4 g/day.. The standard adult dose of CUPRIMINE is: 250-500 mg orally 4 times daily, titrated to maintain urinary copper excretion >2 mg/day. Maximum: 2 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACEPHEN and CUPRIMINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACEPHEN is classified as Category C. Pregnancy Category C. First trimester: potential risk of neural tube defects and orofacial clefts (limited human data, animal studies show embryotoxicity). Second and third trimest. CUPRIMINE is classified as Category C. First trimester: High risk of congenital anomalies including cutis laxa, micrognathia, limb deformities, and CNS defects. Second trimester: Continued risk of fetal harm, potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.